Free Trial
NASDAQ:QURE

uniQure Q3 2023 Earnings Report

uniQure logo
$15.55 -0.15 (-0.96%)
Closing price 08/25/2025 04:00 PM Eastern
Extended Trading
$15.91 +0.36 (+2.32%)
As of 09:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

uniQure EPS Results

Actual EPS
-$1.88
Consensus EPS
-$1.49
Beat/Miss
Missed by -$0.39
One Year Ago EPS
N/A

uniQure Revenue Results

Actual Revenue
$1.41 million
Expected Revenue
$3.33 million
Beat/Miss
Missed by -$1.92 million
YoY Revenue Growth
N/A

uniQure Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 7, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

uniQure's Q3 2025 earnings is scheduled for Tuesday, November 4, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

uniQure Earnings Headlines

uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript
Buffett’s $325 Billion Cash Problem — Solved by Gold?
A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most investors are still asleep… but not for long. Garrett Goggin’s latest research reveals how you can “front-run” the greatest investor alive by positioning in four small miners sitting on up to 100X potential upside. When this hits the news — it’ll be too late.tc pixel
uniQure Narrows Loss in Fiscal Q2
See More uniQure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like uniQure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on uniQure and other key companies, straight to your email.

About uniQure

uniQure (NASDAQ:QURE) develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

View uniQure Profile

More Earnings Resources from MarketBeat